Insights from the San Antonio Breast Cancer Symposium

Conference Coverage

The Role of Granulocyte Colony-Stimulating Factor in the Treatment of Neutropenia in Patients on Sacituzumab Govitecan and its Impact on Therapy Duration

12/06/2023

Edited by Grace Taylor

Using data from a real-world cancer database, Vijay Gorantla, MD, PhD, and colleagues investigated the prevalence of neutropenia in patients treated with sacituzumab govitecan and the role of granulocyte colony-stimulating factor in managing...

Using data from a real-world...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Impact of Implementing Universal Germline Genetic Testing for Breast Cancer in Rural Communities

12/06/2023

Edited by Brandon Twyford

New research underscores the high implementation rate and significant impact of universal germline genetic testing (GGT) for breast cancer (BC) in rural medical practices on shared treatment decision-making.

New research underscores the...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Adverse Event-Related Health Care Utilization and Cost Among Patients with HR+/HER2- Metastatic Breast Cancer

12/06/2023

Edited by Brandon Twyford

Research presented at SABCS 2023 examines the economic impact of treating HR+/HER2- metastatic breast cancer, revealing that costs related to adverse events in patients undergoing late-line chemotherapy treatments are significant and...

Research presented at SABCS 2023...

12/06/2023

Journal of Clinical Pathways

News

Comparing Sacituzumab Govitecan and Physician’s Choice Treatment in HR+/HER2- Metastatic Breast Cancer: TROPiCS-02 Phase 3 Study Analysis

12/06/2023

Edited by: Grace Taylor

Aditya Bardia, MD, and colleagues presented their findings from the TROPiCS-02 phase 3 clinical study, which compared the efficacy of sacituzumab govitecan, a TROP-2 directed antibody-drug conjugate, and treatment of physician’s choice in...

Aditya Bardia, MD, and...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

Study Reveals Insights into Cost-Effectiveness of Multigene Assays in Early-Stage Breast Cancer Treatment

12/06/2023

Edited by Brandon Twyford

A recent study presented at the 2023 ASH Annual Meeting & Exposition compared the cost-effectiveness of four multigene assays used in early-stage breast cancer treatment, and revealed which was the most beneficial for cost savings and...

A recent study presented at the...

12/06/2023

Journal of Clinical Pathways

Conference Coverage

HER2-Low Breast Cancer in the National Cancer Database

12/09/2022

Katie Herman

Daniel Peiffer, MD, PhD, and colleagues discuss a retrospective cohort study comparing clinical characteristics and demographics of HER2-0 vs HER2-low cases.

Daniel Peiffer, MD, PhD, and...

12/09/2022

Journal of Clinical Pathways

Videos

The Impact of HER2-low Status on Prognosis in Hormone Receptor-Positive Metastatic Breast Cancer Treated With a Targeted Therapy Plus Endocrine Therapy

12/08/2022

Jason Mouabbi, MD, discusses his presentation from the 2022 San Antonio Breast Cancer Symposium on survival outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer, finding that HER2-low status may not...

Jason Mouabbi, MD, discusses his...

12/08/2022

Journal of Clinical Pathways

Conference Coverage

HER2-Positive Metastatic Breast Cancer Treatment Patterns in Patients Who Have Received at Least Two Lines of Therapy

12/07/2022

Katie Herman

Della Varghese, PharmD, PhD, and colleagues presented a poster at the 2022 San Antonio Breast Cancer Symposium studying second-line (2L) treatment patterns and outcomes among HER2+ metastatic breast cancer (mBC) patients in the United States.

Della Varghese, PharmD, PhD, and...

12/07/2022

Journal of Clinical Pathways

Conference Coverage

Clinical and Pathological Differences in Breast Cancer Patients With HER2-low and Other Cancer Subtypes

12/07/2022

Katie Herman

Andre Mattar, MD, PhD, and colleagues presented their study at the 2022 San Antonio Breast Cancer Symposium demonstrating significant differences between HER2-low and other cancer subtypes in breast cancer patients.

Andre Mattar, MD, PhD, and...

12/07/2022

Journal of Clinical Pathways

Conference Coverage

Real-World Incidence of Thromboembolic Events in Patients With Metastatic Breast Cancer Treated With Ribociclib

12/07/2021

Janelle Bradley

Study findings show patients with metastatic breast cancer treated with ribociclib plus aromatase inhibitors or fulvestrant are not at higher risk for thromboembolic events.

Study findings show patients...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Budget Impact of Blood-Based Biomarker Assay in Patients With Metastatic Breast Cancer

12/07/2021

Janelle Bradley

Use of a blood-based biomarker assay for patients with metastatic breast cancer reduced the utilization of traditional monitoring and resulted in net savings three times the spend on the assay itself, according to a study presented at the...

Use of a blood-based biomarker...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Biomarker Testing and Alpelisib Treatment Patterns for Metastatic Breast Cancer in the Community Oncology Setting

12/07/2021

Janelle Bradley

A study presented at the 2021 San Antonio Breast Cancer Symposium assessed PIK3CA testing and alpelisib treatment patterns among patients with metastatic breast cancer in the community oncology setting.

A study presented at the 2021...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Oncologists’ Perspectives on Patient-centered Dosing for Metastatic Breast Cancer

12/06/2021

Janelle Bradley

Medical oncologists reported that a high percentage of patients experience distressing toxicity, a need for acute care, and dose interruptions with standard delivery of therapy for metastatic breast cancer.

Medical oncologists reported...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Third-Line Chemotherapy With or Without Trastuzumab-Based Therapy for Metastatic Breast Cancer

12/06/2021

Janelle Bradley

The inclusion of trastuzumab-based therapy with chemotherapy was associated with improved survival outcomes compared with chemotherapy alone for the third-line treatment of metastatic breast cancer.

The inclusion of...

12/06/2021

Journal of Clinical Pathways

Conference Coverage

Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases

12/06/2021

Janelle Bradley

Palbociclib plus letrozole is associated with improved outcomes compared to letrozole alone for the first-line treatment of patients with HR-positive, HER2-negative metastatic breast cancer with lung or liver metastases.

Palbociclib plus letrozole is...

12/06/2021

Journal of Clinical Pathways

Insights from the San Antonio Breast Cancer Symposium

Tracks

Specialties

Events

Year Round Education

HMP Global Products